Lymphoepithelial carcinoma of the maxillary sinus
A case report and review of the literature

Hiromasa Takakura, MD, PhD, Hirohiko Tachino, MD, PhD, Michiro Fujisaka, MD, PhD, Takahiko Nakajima, MD, PhD, Kentaro Yamagishi, MD, PhD, Masayuki Ishida, MD, PhD, Hideo Shojaku, MD, PhD

Abstract
Rationale: Most cases of lymphoepithelial carcinoma (LEC) occur in the nasopharynx, and LEC in the sinonasal tract is extremely rare; thus, the clinical characteristics of sinonasal LEC are not well known.

Patient concerns: A 63-year-old Japanese man presented with a three-week history of left cheek pain, nasal obstruction and cheek swelling.

Diagnoses: Enhanced CT and MRI revealed a tumor of the left maxillary sinus that invaded the left orbit and hard palate, with multiple swollen left cervical lymph nodes. Open biopsy was performed, and the specimen was diagnosed as LEC.

Interventions: Alternating chemoradiotherapy (ALCRT) followed by salvage surgery was performed.

Outcomes: Our patient has been disease free for 5 years.

Lessons: A literature review of the epidemiology, etiology, clinical course and management of sinonasal LEC is highlighted. We believe ALCRT followed by salvage surgery to be a highly optimal treatment for sinonasal LEC from the viewpoint of a balance between quality of life and a high curative effect.

Abbreviations: 5-FU = 5-fluorouracil, ALCRT = alternating chemoradiotherapy, CDDP = cisplatin, CT = computed tomography, EBER = EBV-encoded RNA, EBV = Epstein–Barr virus, FDG = 2-[fluorine-18] fluoro-2-deoxy-D-glucose, MRI = magnetic resonance imaging, NDP = nedaplatin, NPC = nasopharyngeal carcinoma, PET = positron emission tomography, RT = radiotherapy, SUV = standardized uptake value.

Keywords: alternating chemoradiotherapy, Epstein–Barr virus (EBV), lymphoepithelial carcinoma, maxillary sinus, sinonasal tract

1. Introduction

Lymphoepithelial carcinoma (LEC) consists of poorly differentiated squamous cell carcinoma or histologically undifferentiated carcinoma accompanied by prominent reactive lymphoplasmacytic infiltration. Most cases of LEC occur in the nasopharynx and are pathologically classified as a nonkeratinizing undifferentiated type of nasopharyngeal carcinoma (NPC). Although LEC is generally rare, when present, it tends to be located in various sites in the head and neck, including the salivary glands, oral cavity, oropharynx, larynx, hypopharynx, lungs, and esophagus. LEC involving the sinonasal tract is rare, especially in the maxillary sinus. Sinonasal LEC is more common in Southeast Asia, where the incidence of NPC is higher than that in Western countries. Sinonasal LEC is extremely rare in other countries, including Japan, and its clinical characteristics remain unknown.

We herein report a case of LEC of the left maxillary sinus with cervical lymph node metastasis in which 5-year disease-free survival was achieved, and we review the literature on sinonasal LEC.

2. Case report

A 63-year-old Japanese man with a previous history of heavy smoking (20 cigarettes/d × 40 years) and alcohol consumption presented to our hospital in December 2010 with a 3-week history of left cheek pain, nasal obstruction, and cheek swelling. He had no accompanying history of epistaxis, headache, or visual disturbance. His medical history included atrial fibrillation, diabetes mellitus, hypertension and ureteral stone, and his surgical history included operations for appendicitis and sinusitis. An inspection of the nasal cavity with a soft fiberscope revealed inward displacement of the left inferior turbinate and blockage of the left common nasal meatus (Fig. 1A). A physical examination indicated swelling of his left cheek, left upper gingiva, and left hard palate (Fig. 1B). Enhanced computed tomography (CT) and magnetic resonance imaging (MRI) revealed a 38 × 48 × 50-mm tumor located in the left maxillary sinus that was heterogeneously enhanced with bony destruction of the superior, posterior, and lateral walls, and parts of the anterior wall of the left maxillary sinus (Figs. 2
Additionally, EBV serology revealed serum IgG antibodies against the EBV capsid antigen (EBV VCA IgG), serum IgA antibodies against the EBV capsid antigen (EBV VCA IgA), and EBV early antigen (EBV EA IgA) at titers of 1:1280, 1:20, and 1:40, respectively. Based on the clinical, radiological, and pathological findings, a final diagnosis of LEC of the left maxillary sinus with left cervical lymph node metastases (T3N2bM0, stage IVA) was made. His glomerular filtration rate was 55.3 mL/min, suggesting that he had poor renal function due to diabetes mellitus.

Alternating chemoradiotherapy (ALCRT) was performed to treat the LEC of the maxillary sinus based on the regimen for NPC because LEC is common in patients with NPC and because we thought that it might also be effective for LEC of the maxillary sinus. Figure 6 shows a schematic illustration that summarizes the treatment protocol. Although 3 courses of chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) and 2 courses of radiotherapy (RT) were performed alternately in the original ALCRT regimen, nedaplatin (NDP) instead of CDDP was used to avoid renal dysfunction due to CDDP. In our chemotherapy regimen, 5-FU at a dose of 1000 mg/m² per 24 hours was administered in a 24-hour intravenous infusion for 120 hours, followed by a 24-hour infusion of NDP at a dose of 100 mg/m² per 24 hours (day 6). During the course of ALCRT, the first course of chemotherapy (with a 25% dose reduction) was administered before RT, and RT (Field A) was then performed for 4 weeks, starting from 3 days after the completion of chemotherapy. The second course of chemotherapy (full-dose) was administered to 2 to 3 days after the completion of RT. The second course of RT (Field B) was then administered with a reduced irradiation field 3 days after the second chemotherapy session. The third course of chemotherapy was administered 3 days after the completion of the second course of RT; the dose was reduced by 25% again because of the progression of renal and liver dysfunction after the second chemotherapy and RT sessions. RT was performed with a daily fraction of 1.8 Gy from day 10 to 37 and 2 Gy from day 49 to 71. The initial radiation field covered the area between the left maxilla and the whole left cervical and clavicular region, and RT (36 Gy/20 fractions) was performed using the 3 fields technique for conformal irradiation (Field A). Then, a smaller field was selected for the left maxillary tumor, which was treated with a dose of 34 Gy/17 fractions using the 2 fields technique for conformal irradiation (Field B).

The response to ALCRT was evaluated according to the RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. The tumor reduction effect was considered to represent a partial response. Multiple hypertrophy of the left cervical lymph nodes disappeared, and the strong uptake of FDG in the left cervical lymph nodes also disappeared or normalized. Thus, the effect of ALCRT with regard to lymph node metastasis was considered to represent a complete response. Neck dissection was not performed on this patient.

At approximately 6 months after the first presentation, salvage surgery (extensive Denker’s operation) of the residual maxillary tumor was performed to confirm whether any cancer cells remained. A histopathological examination revealed no evidence of residual cancer cells in the surgical specimen.

Finally, the patient has been disease-free for 5 years following the operation. Our patient is quite satisfied with the treatment because of the few side effects, low cosmetic and functional disturbance and complete recovery from the disease. Ethical approval for this report was waived because approval for case
reports is not required in our institution. The patient has given informed consent for the publication of this case report.

3. Discussion

3.1. Relationship between LEC and EBV

LEC of the nasopharynx and some other sites have shown a strong association with EBV. Numerous serologic, immunofluorescence and nucleic acid hybridization studies have strongly linked EBV to NPC. EBER is strongly expressed by the tumor cells in such cases, indicating the presence of EBV RNA. Similarly to NPC, EBV is strongly associated with the pathogenesis of LEC of the sinonasal tract, however, some cases are EBV negative. Sckolnick et al. suggested that the occurrence of LEC in endemic areas, such as Southeast Asia, is associated with EBV infection. In contrast, LEC is not commonly associated with EBV in Western countries. Our patient was positive for EBER, and it is possible that EBV might have been associated with the occurrence of his left maxillary LEC.

3.2. Clinical characteristics of sinonasal LEC

In 2011, Rytkönen et al. reported a literature review of 6 cases of sinonasal LEC, including 1 case in which LEC originated from the nasolacrimal duct. Based on their review, we also reviewed the literature on sinonasal LEC to include studies that were published after 2011 and the present case (Table 1). We excluded cases of LEC originating from the nasolacrimal duct in our review. We found only 8 case reports of sinonasal LEC that included detailed patient information in the English literature from 1980 to 2016. LEC originating from the
maxillary sinus occurred in only 4 of the 8 cases. The mean patient age in these 8 cases was 47.4 (range: 21–72) years; 5 of the patients were men and 3 were women. The clinical symptoms of the patients included epistaxis (n = 6; 75.0%), pain or headache (n = 4; 50.0%), nasal obstruction (n = 4; 50.0%), facial swelling (n = 3; 37.5%), and loss of taste and smell (n = 1; 12.5%). The tumor sites were the maxillary sinus (n = 4), nasal cavity (n = 3), and nasal cavity and ethmoid sinus (n = 1). The mean duration of symptoms was 3.0 months. Four of the 8 cases were EBV positive. Cervical lymph node metastasis was not detected in the 8 cases; however, it was detected in our case. Distant metastasis was not found in any of the 8 cases or in our patient. The disease stages of the patients were stage I (n = 3), stage II (n = 1), stage III (n = 3), and stage IV (n = 1). The treatment strategies differed between patients with locoregional (stage I/II) and advanced (stage III/IV) disease. Surgical removal was selected...
as the initial treatment for all 4 patients with locoregional disease. Radiotherapy and chemoradiotherapy were subsequently performed as postoperative adjuvant therapy for 1 patient and 2 patients, respectively. In contrast, chemoradiotherapy and radiotherapy were selected as the initial treatments for 3 patients and 4 patients with advanced disease, respectively. The mean follow-up period was 33 (range: 11–36) months, and no relapse or residual tumor was found in any of the 6 patients described in the literature.

The literature contains 2 case series on sinonasal LEC. The authors of both studies belonged to institutions in areas with a high incidence of EBV-positive NPC (Guangzhou and Taipei in Figure 4. Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG). FDG PET/CT showed strong uptake of FDG in the left maxillary sinus (SUV = 37.6) (A), lymph nodes in the left parapharyngeal space (SUV = 16.6) (B), left tonsil (SUV = 25.6) (C), left submandibular lymph nodes (SUV = 17.4) (D), and left supraclavicular lymph nodes (SUV = 10.2) (E).
Southeast Asia).\cite{14,21} Thirty-three patients (all EBV positive) were enrolled in these studies.

Zong et al\cite{14} reported the pathological characteristics of sinonasal LEC. LEC originating from the maxillary sinus was found in 3 cases (15.0%). Cervical lymph node metastasis was found in 3 of 20 sinonasal LECs (15%), indicating that the frequency of lymph node metastasis in sinonasal LEC was smaller than that in nasopharyngeal LEC. However, the treatments and the clinical prognoses were not indicated in their report.

Jeng et al\cite{21} investigated the clinical and histopathological characteristics of primary sinonasal nasopharyngeal-type carcinoma (referred to as sinonasal LEC in the present paper). In their paper, 13 patients (male, n=9; female, n=4) were analyzed. The most common location was the nasal cavity and septum (n=8;
61.5%). In 5 cases, the tumors were located in the maxillary sinus (38.5%), orbital and intracranial invasion was seen in 4 (31%) and 2 (15%) cases, and cervical node metastasis was detected in 3 cases (23%). Distant metastasis to the bone and other sites was only detected in 1 case. The treatments included radiotherapy (n = 10) and surgical resection (n = 7). Chemotherapy was administered to 3 patients. Two patients died of disease at 7 months and 62 months, respectively, after the diagnosis. Eight patients (61%) were disease free at their last follow-up examination (median follow-up time: 48 months).

### 3.3. Treatment for sinonasal LEC

A standard treatment approach for sinonasal LEC has not been established because of the rarity of reported cases. Non-nasopharyngeal LEC of the head and neck is a highly radiosensitive disease for which excellent local control rates can be achieved with radiotherapy. [23] Dubey et al. [24] suggested that radiotherapy is an appropriate initial locoregional therapy for patients with this disease. They recommended systemic therapy with chemotherapy for non-nasopharyngeal LEC patients who present with regional adenopathy because they have a relatively high rate of distant metastasis. Furthermore, they suggested that surgery should be reserved for patients who have persistent disease after the completion of radiotherapy. [22]

ALCRT is a minor variation of concurrent chemoradiation aimed at minimizing toxicity. [25] In Japan, ALCRT with 3 courses of chemotherapy, consisting of 5-FU and CDDP, and 2 courses of radiotherapy, which are sandwiched with the chemotherapy, has been used for the treatment of locoregional advanced NPC in many institutions. [26] This method of ALCRT yielded higher or at least similar survival rates and lower toxicities in comparison with concurrent chemoradiation for NPC. [27] The 5-year overall survival and progression-free survival rates were 78.04% (95% CI: 69.1%–87.0%), and 68.74% (95% CI: 58.8%–78.7%), respectively. [24] NDP, a derivative of CDDP that was developed in Japan, was used in our patient to avoid the renal dysfunction that may develop in association with the administration of CDDP. This antitumor agent has shown promising activity in cervical cancer and is associated with less renal and gastrointestinal toxicity. [28] Previous studies have indicated that ALCRT with 5-FU and NDP is feasible and effective for patients with head and neck cancer, [24] esophageal cancer, [27] and advanced cervical carcinoma. [28]

The tumor in our patient invaded the left orbit and hard palate. If surgical removal had been selected as the initial treatment, we would have had to select total maxillectomy, and the patient might have suffered cosmetic and functional disturbance due to the loss of the left eye and hard palate. Thus, we selected ALCRT with 5-FU and NDP as the initial treatment, followed by salvage surgery for the residual tumor, out of consideration for the patient’s quality of life and treatment results. Treatment resulted in partial response of the regional tumor and complete response of the cervical lymph node metastasis, and pathological complete response of the regional tumor was confirmed by salvage surgery. Mild renal dysfunction occurred during ALCRT with NDP, but the patient recovered after the NDP dose was reduced. Our patient could complete the ALCRT regimen without a break and ultimately has been disease free for 5 years. We believe that ALCRT with 5-FU and NDP followed by salvage surgery is one of the most effective treatments for LEC of the sinonasal tract from the viewpoint of balancing the quality of life with high curative effect.

### 4. Conclusion

We treated an extremely rare case of LEC of the left maxillary sinus that invaded the left orbit and hard palate with cervical lymph node metastasis. Five-year disease-free survival was achieved without cosmetic or functional disturbance. To our knowledge, this is the first case of LEC of the maxillary sinus treated with ALCRT followed by salvage surgery, which can be expected to have a high curative effect with few side effects.

### Author contributions

**Conceptualization:** Hiromasa Takakura, Hideo Shojaku.  
**Data curation:** Hirohiko Tachino, Michiro Fujisaka, Kentaro Yamagishi.  
**Formal analysis:** Hiromasa Takakura, Masayuki Ishida.  
**Investigation:** Hideo Shojaku.

---

**Table 1**  
A summary of the review of the literature on sinonasal lymphoepithelial carcinoma (LEC), including the present case.

| Report       | Age | Sex | Side | Symptoms                          | Tumor site/size | Duration of symptoms | Metastases | TNM stage | Treatment | EBV | Follow-up | Relapse or residual |
|--------------|-----|-----|------|-----------------------------------|-----------------|----------------------|------------|------------|-----------|-----|-----------|---------------------|
| Takakura (2018) | 63  | M   | L    | Cheek pain, nasal obstruction and cheek swelling | Maxillary sinus/38 x 48 x 50 mm | 17 days | Yes | T3N2M0 stage III | CR+5F+ | + | 5 yr | No |
| Muthyam (2014) | 45  | F   | R    | Painful swelling of the face, epistaxis | Maxillary sinus/35 x 30 mm | 2 mo | No | T3N0M0 stage II | R | – | 20 mo | No |
| Mohammed (2012) | 72  | M   | R    | Epistaxis | Maxillary sinus/3 | 3 mo | No | T1N0M0 stage I | Sm=RC | – | 3 yr | No |
| Kim (2012) | 21  | M   | R    | Nasal stufiness, epistaxis | Nasal cavity/45 | 4 mo | No | T2N0M0 stage II | Sm=RC | + | 15 mo | No |
| Rydén (2011) | 30  | M   | L    | Mild pain and discomfort of the left upper molars, epistaxis | Maxillary sinus/5 | 5 mo | No | T2N0M0 stage II | Sm=RC | – | 11 mo | No |
| Trabelsi (2010) | 58  | M   | R    | Nasal obstruction, epistaxis | Nasal septum/30 x 50 mm | 2 mo | No | T3N0M0 stage III | Cr=5 (inc) | + | 12 mo | No |
| Jung (2009) | 64  | F   | R    | Swelling on the right side of the face | Maxillary sinus/5 x 5 cm | 3 mo | No | T3N0M0 stage III | Sm=RC | – | 36 mo | No |
| Halajansou (2006) | 33  | M   | R    | Headache, persistent nasal congestion, loss of smell and taste, epistaxis | Nasal cavity, ethmoid sinus/5 | 2 mo | No | T4N0M0 stage IIB | Cr | + | n/a | n/a |
| Wickel (1996) | 56  | M   | R    | Not available | Not available | Not available | Not available | Not available | Not available | Not available | Not available | Not available |

A summary of the review of the literature on sinonasal lymphoepithelial carcinoma (LEC), including the present case.  

– = negative, + = positive, S = chemotherapy, EBV = Epstein–Barr virus, F = female, mo = months, M = male, n/a = not available, R = radiotherapy, S = surgery, yr = years.

---

Formal analysis: Hiromasa Takakura, Hideo Shojaku.  
Conceptualization: Hiromasa Takakura, Hideo Shojaku.  
Data curation: Hirohiko Tachino, Michiro Fujisaka, Kentaro Yamagishi.  
Investigation: Hideo Shojaku.
Methodology: Michiro Fujisaka, Takahiko Nakajima, Kentaro Yamagishi.

Supervision: Takahiko Nakajima, Kentaro Yamagishi, Hideo Shojaku.

Validation: Hirohiko Tachino, Michiro Fujisaka, Masayuki Ishida.

Visualization: Takahiko Nakajima.

Writing – original draft: Hiromasa Takakura.

Writing – review & editing: Hideo Shojaku.

References

[1] Tsang WYW, Chan JKC, Barnes L, Eveson JW, Reichart P, Sidransky D. Lymphoepithelial carcinoma. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours IARC Press, Lyon:2003:18.

[2] Mohammed D, Jabar A, Philippe M, et al. Lymphoepithelial carcinoma in the maxillary sinus: a case report. J Med Case Rep 2012;6:416.

[3] Skolnick J, Murphy J, Hunt JL. Microsatellite instability in nasopharyngeal and lymphoepithelial carcinomas of the head and neck. Am J Surg Pathol 2006;30:1250–3.

[4] Bansberg S, Olsen K, Gaffey T. Lymphoepithelioma of the oropharynx. Otolaryngol Head Neck Surg 1985;100:303–7.

[5] Stanley R, Weiland L, DeSanto L, et al. Lymphoepithelioma (undifferentiated carcinoma) of the laryngohypopharynx. Laryngoscope 1985;95:1077–81.

[6] Tozer C, Peterson D. Lymphoepithelioma of the vocal cord. Arch Otolaryngol 1978;104:161–2.

[7] Micheau C, Luboinski B, Schwab G, et al. Lymphoepitheliomas of the larynx (undifferentiated carcinomas of nasopharyngeal type). Clin Otolaryngol 1979;4:43–8.

[8] Ferlito A, Primary lymphoepithelial carcinoma of the hypopharynx. J Laryngol Otol 1977;91:361–7.

[9] Frank DK, Cheron F, DiCostanzo D, et al. Nonnasopharyngeal lymphoepithelomas (undifferentiated carcinomas) of the upper aerodigestive tract. Ann Otol Rhinol Laryngol 1995;104:305–10.

[10] Cleary K, Batsakis J. Undifferentiated carcinoma with lymphoid stroma of the major salivary glands. Ann Otol Rhinol Laryngol 1990;99:236–8.

[11] Rytkonen AE, Hirvikoski PF, Salo TA. Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. Head Neck Pathol 2011;5:327–34.

[12] Wenig BM. Lymphoepithelial-like carcinomas of the head and neck. Semin Diagn Pathol 2015;32:74–86.

[13] Iezzi M, Gaffey M, Weiss L. The role of Epstein-Barr virus in lymphoepithelial-like carcinomas. Am J Clin Pathol 1995;103:308–15.

[14] Zong Y, Liu K, Zhong B, et al. Epstein-Barr virus infection of sinonasal lymphoepithelial carcinoma in Guangzhou. Chin Med J 2001;114:132–6.

[15] Jung H, Park SK, Heo KW, et al. Lymphoepithelial carcinoma of the maxillary sinus with orbital invasion. Auris Nasus Larynx 2009;36:487–90.

[16] Mathayam SR, Kaushik R, Pushpanshu K, et al. Lymphoepithelial carcinoma arising from the maxillary antrum: a clinicopathological report of a rare lesion in an unusual site. Quant Imaging Med Surg 2014;4:512–5.

[17] Kim YH, Kim BJ, Jang TY. Lymphoepithelial carcinoma of the nasal cavity mimicking juvenile angiofibroma. Auris Nasus Larynx 2012;39:519–22.

[18] Trabelsi A, Tebra S, Abdelkrim SB, et al. Lymphoepithelial carcinoma of the nasal cavity with EBV infection in a North African man. World J Oncol 2010;1:91–3.

[19] Hajiioannou JK, Kyrizakis DE, Datseris G, et al. Nasopharyngeal-type undifferentiated carcinoma (lymphoepithelioma) of paranasal sinuses: Rare case and literature review. J Otolaryngol 2006;35:147–51.

[20] Wöckel W, Wernert N. Excessive epithelioid cell granulomatous reaction associated with a lymphoepithelial carcinoma (Schmincke-Regaud). Pathol Res Pract 1986;181:349–56.

[21] Jing YM, Sung MT, Fang CL, et al. Sinonasal undifferentiated carcinoma and nasopharyngeal-type undifferentiated carcinoma: two clinically, biologically, and histopathologically distinct entities. Am J Surg Pathol 2002;26:371–6.

[22] Dubey P, Ha CS, Ang KK, et al. Nonnasopharyngeal lymphoepithelioma of the head and neck. Cancer 1998;82:1556–62.

[23] Merlano M. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist 2006;11:146–51.

[24] Fuwa N, Kodaira T, Daimon T, et al. The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multinational phase II study. Cancer Med 2015;4:1186–95.

[25] Kodaira T, Fuwa N, Nakaniishi T, et al. Prospective study of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multinational phase II study. Cancer Med 2015;4:1186–95.

[26] Fuwa N, Kodaira T, Tachibana H, et al. Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with high-risk group with cervical carcinoma. Int J Radiat Oncol Biol Phys 2009;73:251–8.

[27] Fuwa N, Kodaira T, Tachibana H, et al. Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer. Jpn J Clin Oncol 2007;37:161–7.

[28] Kodaira T, Fuwa N, Kamata M, et al. Single-institute phase III trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma. Anticancer Res 2006;26:471–8.